Send to a Friend Share

Cantor Fitzgerald Upgrades Sequenom (SQNM) to Buy

March 2, 2010 9:32 AM EST
SQNM Hot Sheet
Rating Summary:
    7 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 16 | Down: 7 | New: 23
Cantor Fitzgerald upgrades Sequenom (Nasdaq: SQNM) from Hold to Buy with a $16 price target.

The firm commented, "Following our recent meeting with management, settlement of the consolidated class action suit and recent advances signaling pipeline progress — including Sequenom's previously launched MassARRAY Compact 96 System and SensiGene Cystic Fibrosis (CF) Carrier Screening Test plus the launch of SensiGene Fetal RHD Genotyping and SensiGene FetalXY (fetal sex determination) tests in February with independent clinical studies are underway — have renewed our confidence that Sequenom is back on-track toward building its molecular diagnostics portfolio on the foundation of its genome analysis platform."

Cantor said Sequenom's commitment to launching its next-gen MassARRAY platform will be a key driver of long-term growth.

You May Also Be Interested In


Related Categories

Momentum Movers, Upgrades

Related Entities

Cantor Fitzgerald

Add Your Comment





Follow StreetInsider.com On Twitter